olivLaw · US equity research
Smith+Nephew plc SNN
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842 · Vertical: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Smith+Nephew is a UK-based medical technology group focused on repair, regeneration and replacement of soft and hard tissue, with products in orthopaedics, sports medicine, ENT and advanced wound management. In 2025 it completed its 12-Point Plan transformation and launched the RISE strategy for 2026-2028, making its ability to accelerate growth relevant now. Revenue grew 6.1%, with group revenue of 6.164 bn USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Smith+Nephew plc (SNN) stock was 32.46 USD (+7.59% on the day), with market capitalisation 28.5 bn USD, P/E 45.3 on diluted EPS of 0.72 USD over the last 12 months, beta 0.45, 52-week range 26.42–36.90 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 74.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 26.71 – 32.15
- above the upper band · %B 1.06 · band width 18.5%
- SMA 50 / 200
- 28.41 / 31.04
- mixed trend
- MACD (12, 26, 9)
- 0.81 / 0.62
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +20.6% | −1.1% | +21.7 pp | — |
| 3 months | +7.7% | −0.5% | +8.2 pp | — |
| 6 months | +7.3% | +4.4% | +2.9 pp | — |
| Year to date | −1.1% | +12.3% | −13.4 pp | — |
| 1 year | −12.3% | +13.5% | −25.9 pp | +2.0% |
| 3 years | +34.8% | +76.4% | −41.6 pp | −4.2% |
| 5 years | −12.6% | +63.7% | −76.3 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 30 percentile of its own 10-quarter history (min 0.5, median 55.1, max 105.5; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.9 bn | 5.1 bn | 4.6 bn | 5.2 bn | 5.2 bn | 5.5 bn | 5.8 bn | 6.2 bn |
| Revenue YoY | +2.9% | +4.8% | −11.2% | +14.3% | +0.1% | +6.4% | +4.7% | +6.1% |
| Net income | 663.0 m | 600.0 m | 448.0 m | 524.0 m | 223.0 m | 263.0 m | 412.0 m | 625.0 m |
| Net income YoY | −13.6% | −9.5% | −25.3% | +17.0% | −57.4% | +17.9% | +56.7% | +51.7% |
| Diluted EPS | 75.70 | 0.60 | 0.51 | 0.60 | 0.26 | 0.30 | 0.47 | 0.72 |
| Diluted EPS YoY | +8,531.7% | −99.2% | −14.2% | +16.6% | −57.3% | +18.0% | +56.1% | +52.3% |
| net % | 13.5% | 11.7% | 9.8% | 10.1% | 4.3% | 4.7% | 7.1% | 10.1% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 557.0 m USD
- Financial debt
- 83.0 m USD
- Net debt
- -474.0 m USD
- Equity
- 5.3 bn USD
- Total assets
- 10.5 bn USD
- Debt / equity
- 0.02x
- Current ratio
- 2.57x
- ROE
- 11.8%
- ROA
- 6.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 4.6 bn | 5.2 bn | 5.2 bn | 5.5 bn | 5.8 bn | 6.2 bn | SEC (XBRL)· 16 Mar 2026verified |
| Cost of revenue | 1.4 bn | 1.5 bn | 1.5 bn | 1.7 bn | 1.8 bn | 2.0 bn | SEC (XBRL)· 16 Mar 2026verified |
| Gross profit | 3.2 bn | 3.7 bn | 3.7 bn | 3.8 bn | 4.0 bn | 4.2 bn | SEC (XBRL)· 16 Mar 2026verified |
| Research & development | 307.0 m | 356.0 m | 345.0 m | 339.0 m | 289.0 m | 296.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Operating income | 295.0 m | 593.0 m | 450.0 m | 425.0 m | 657.0 m | 794.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Pre-tax income | 246.0 m | 586.0 m | 235.0 m | 290.0 m | 498.0 m | 779.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Income tax | -202.0 m | 62.0 m | 12.0 m | 27.0 m | 86.0 m | 154.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Net income | 448.0 m | 524.0 m | 223.0 m | 263.0 m | 412.0 m | 625.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Diluted EPS | 0.51 | 0.60 | 0.26 | 0.30 | 0.47 | 0.72 | SEC (XBRL)· 16 Mar 2026verified |
| Weighted average diluted shares | 877.0 m | 878.0 m | 873.0 m | 873.0 m | 876.0 m | 873.0 m | SEC (XBRL)· 16 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 1.8 bn | 1.3 bn | 350.0 m | 302.0 m | 619.0 m | 557.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Receivables | 1.1 bn | 1.2 bn | 1.3 bn | 1.3 bn | 1.4 bn | 1.4 bn | SEC (XBRL)· 16 Mar 2026verified |
| Inventories | 1.7 bn | 1.8 bn | 2.2 bn | 2.4 bn | 2.4 bn | 2.1 bn | SEC (XBRL)· 16 Mar 2026verified |
| Current assets | 4.7 bn | 4.4 bn | 3.9 bn | 4.0 bn | 4.4 bn | 4.1 bn | SEC (XBRL)· 16 Mar 2026verified |
| Property, plant & equipment, net | 1.4 bn | 1.5 bn | 1.5 bn | — | — | — | SEC (XBRL)· 06 Mar 2023verified |
| Goodwill | 2.9 bn | 3.0 bn | 3.0 bn | 3.0 bn | 3.0 bn | 3.1 bn | SEC (XBRL)· 16 Mar 2026verified |
| Intangibles (excl. goodwill) | 1.5 bn | 1.4 bn | 1.2 bn | 1.1 bn | 1.0 bn | 882.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Total assets | 11.0 bn | 10.9 bn | 10.0 bn | 10.0 bn | 10.4 bn | 10.5 bn | SEC (XBRL)· 16 Mar 2026verified |
| Accounts payable | 1.0 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.2 bn | SEC (XBRL)· 16 Mar 2026verified |
| Short-term debt | 279.0 m | 435.0 m | 111.0 m | 710.0 m | 2.0 m | 83.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Current liabilities | 1.7 bn | 2.1 bn | 1.7 bn | 2.3 bn | 1.5 bn | 1.6 bn | SEC (XBRL)· 16 Mar 2026verified |
| Total liabilities | 5.7 bn | 5.4 bn | 4.7 bn | 4.8 bn | 5.1 bn | 5.2 bn | SEC (XBRL)· 16 Mar 2026verified |
| Equity | 5.3 bn | 5.6 bn | 5.3 bn | 5.2 bn | 5.3 bn | 5.3 bn | SEC (XBRL)· 16 Mar 2026verified |
| Shares outstanding at year end | 884.9 m | 885.2 m | 877.6 m | 877.7 m | 877.7 m | 877.7 m | SEC (XBRL)· 16 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 935.0 m | 877.0 m | 468.0 m | 608.0 m | 987.0 m | 1.3 bn | SEC (XBRL)· 16 Mar 2026verified |
| Investing cash flow | -606.0 m | -691.0 m | -472.0 m | -448.0 m | -569.0 m | -406.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Financing cash flow | 1.2 bn | -645.0 m | -926.0 m | -200.0 m | -86.0 m | -955.0 m | SEC (XBRL)· 16 Mar 2026verified |
| Share repurchases | 16.0 m | — | 158.0 m | — | — | 502.0 m | SEC (XBRL)· 16 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 54.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 28.5 bn USD
Key indicators
Coverage and freshness
Score by group
54% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 16.97 – 28.24 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E16.97 – 28.24 (Mid 20.72)8 companies used · median multiple 28.9x · quartiles 23.7x – 39.4xALGN, APT, CDRE, EW, ISRG, MSA, STE, ZBH
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 54.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 13.5% | 82 (vs peers) | 19% |
| Net margin · Quality | 10.1% | 77 (vs peers) | 12% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 5.7% | 48 (on a fixed band) | 15% |
| EPS CAGR 3Y · Growth | 41.1% | 100 (on a fixed band) | 15% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.6x | 100 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | 45.3x | 33 (vs peers) | 19% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 1.8% | 25 (on a fixed band) | 12% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth74/100 · 2/2 factors with a value
- Quality80/100 · 2/3 factors with a value
- Returns· partial25/100 · 1/2 factors with a value
- Valuation· partial33/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Smith & Nephew plc (SNN). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 6.2 bn USD in 2025; YoY growth 6.1%; net margin 10.1%; ROE 11.8%.
The estimated value range is 16.97–28.24 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 20.72 USD, the price of 32.46 USD leaves a potential of -36.2% (value / price − 1) and a margin of safety of -56.7% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 54.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 13.5%
- Net margin: 10.1%
- EPS CAGR 3Y: 41.1%
- Current ratio: 2.6x
What contradicts it
- Shareholder yield (distributions): 1.8%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Net debt / EBITDA, Interest coverage, EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 167.1 bn | 58.3 | 18.0% | 25.5% | +20.5% | −16% / +55% |
| EWEdwards Lifesciences Corporation | 57.1 bn | 56.2 | 9.7% | 15.3% | +11.5% | +15% / +47% |
| SNNSmith & Nephew plc | 28.5 bn | 45.3 | 11.8% | 10.1% | +6.1% | −12% / +35% |
| STESTERIS plc | 24.2 bn | 30.0 | 11.4% | 13.3% | +8.7% | −7% / +23% |
| ZBHZimmer Biomet Holdings, Inc. | 20.8 bn | 27.9 | 6.0% | 9.0% | +7.2% | +13% / −5% |
| ALGNAlign Technology, Inc. | 11.6 bn | 24.0 | 11.9% | 11.8% | +0.9% | +12% / −23% |
| MSAMsa Safety Inc | 6.8 bn | 22.8 | 22.1% | 15.0% | +3.7% | +10% / +2% |
| ESTAEstablishment Labs Holdings Inc. | 2.0 bn | — | -175.3% | -15.8% | +27.1% | −3% / +161% |
| ENOVEnovis Corp | 1.4 bn | — | -54.3% | -48.0% | +6.7% | −19% / −51% |
| CDRECadre Holdings, Inc. | 1.3 bn | 33.8 | 11.6% | 5.6% | +7.5% | −28% / −4% |
| AVRAnteris Technologies Global Corp. | 596.4 m | — | -75.1% | -4,619.3% | −29.2% | +49% / unavailable |
| COCHEnvoy Medical, Inc. | 549.6 m | — | — | -11,304.8% | +7.1% | +749% / +216% |
| ZJYLJin Medical International Ltd. | 483.7 m | 309.0 | 4.1% | 5.8% | −12.0% | −39% / −87% |
| SMTISanara Medtech Inc. | 297.0 m | — | -147.7% | -29.2% | +19.0% | +55% / −0% |
| INGNInogen, Inc. | 191.6 m | — | -13.1% | -6.9% | +3.9% | +2% / +24% |
| LAKELakeland Industries, Inc. | 88.7 m | — | -19.6% | -14.0% | +15.2% | −41% / −39% |
| NTRBNutriband Inc. | 73.9 m | — | -100.7% | -430.4% | −4.8% | +23% / +140% |
| APTAlpha Pro Tech, Ltd. | 58.6 m | 14.1 | 6.6% | 6.8% | +2.3% | +25% / +17% |
| CLGNCollPlant Biotechnologies Ltd | 54.2 m | — | -117.6% | -484.6% | +360.4% | −81% / −92% |
| MYOMyomo, Inc. | 51.5 m | — | -123.8% | -33.5% | +25.7% | +46% / −58% |
| MLSSMilestone Scientific Inc. | 29.2 m | — | -121.7% | -44.0% | +4.0% | +6% / −61% |
| LFWDLifeward Ltd. | 17.2 m | — | -225.6% | -141.3% | −14.1% | −13% / −90% |
| CUPRCuprina Holdings (Cayman) Limited | 14.1 m | — | -1,115.0% | -9,366.7% | +9.2% | −64% / unavailable |
| BBLGBone Biologics Corporation | 1.2 m | — | -47.5% | — | 0.0% | −77% / −98% |
1- and 3-year price returns: for SNN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 19.32 Total return -40% · Per year -40% | 34.13 Total return 5% · Per year 5% | 51.38 Total return 58% · Per year 58% |
| 3 years | 19.21 Total return -41% · Per year -16% | 38.16 Total return 18% · Per year 6% | 63.00 Total return 94% · Per year 25% |
| 5 years | 19.11 Total return -41% · Per year -10% | 42.66 Total return 31% · Per year 6% | 77.25 Total return 138% · Per year 19% |
- Exit P/E± 9.54
- Net margin± 6.68
- Annual revenue growth± 5.42
- Annual dilution± 0.56
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 16 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Nov 2026), 6-K (22 Oct 2026), 6-K (08 Oct 2026), 6-K (01 Oct 2026).
In brief
Smith+Nephew is a UK-based medical technology group focused on repair, regeneration and replacement of soft and hard tissue, with products in orthopaedics, sports medicine, ENT and advanced wound management. In 2025 it completed its 12-Point Plan transformation and launched the RISE strategy for 2026-2028, making its ability to accelerate growth relevant now. Revenue grew 6.1% 1, with group revenue of 6.164 bn USD 1.
SWOT
Strengths
- Diversified portfolio across three global business units, with strong cash generation and a recent record of operational improvement 1.
- Active innovation programme with many product launches in recent years, contributing a large share of revenue growth 1.
- Management team that met its annual commitments throughout the transformation programme 1.
Weaknesses
- The orthopaedics segment has been weaker and remains under pressure, especially in US knee implants 1.
- Adjusted return on invested capital is still relatively modest, weighed down by portfolio rationalisation 1.
- Reliance on specific markets and on centralised procurement tenders in certain countries could limit revenue in periods of pressure 1.
Opportunities
- Expanding patients treated and market share in sports medicine, wound management and ENT, as set out in the RISE strategy 1.
- The shift of joint replacement into ambulatory centres could favour the company's robotic systems 1.
- Generated cash could fund strategic acquisitions and investment in emerging markets 1.
Risks
- Execution of the RISE programmemedium
The 2028 growth and cash flow targets depend on executing the plan, and launch delays could affect results.
- US knee segmentmedium
Weak performance of US knee systems could limit progress in orthopaedics until the new system is launched.
- Pressure in Chinahigh
Centralised procurement and lower prices in China could continue to weigh on revenue and margins.
- Geopolitical and supply risksmedium
Geopolitical tensions and reliance on complex supply chains could disrupt production.
- Regulation and compliancelow
Regulatory changes and compliance requirements could delay launches or raise costs.
Investment thesis
What would need to be true (bull case)
- If the RISE programme meets its targets, organic growth could accelerate and trading profit margin could keep improving.
- Strong cash generation could fund innovation and acquisitions, strengthening positions in sports medicine and wound management.
- Structural demand in medical technology, supported by demographics and innovation, could sustain long-term growth.
What would break the thesis
- If pricing pressure in China and from public systems persists, margins could stay below targets.
- The orthopaedics segment could recover more slowly than expected, limiting margin expansion.
- Strategic acquisitions could bring integration risks and reduce cash available for other investments.
What to watch
- Progress of organic growth against the 6-7% annual target for 2026-20282026
- Launch of the LANDMARK knee system and its effect on the US segmentSecond half 2026
- Trajectory of orthopaedics trading profit margin against the expansion target2027
- Integration of Integrity Orthopaedics and effects on sports medicinenext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 16 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Nov 2026), 6-K (22 Oct 2026), 6-K (08 Oct 2026), 6-K (01 Oct 2026).
The business
According to the 2025 annual report 1, the company defines its purpose as 'Life Unlimited' and operates three global business units: Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Group revenue was 6.164 bn USD in 2025 1. The company operates in growth markets valued at more than 50 bn USD annually 1.
Segments
Advanced Wound Management
The largest business unit by revenue share, offering products and services for hard-to-heal wounds. The segment contributed 2.437 bn USD in 2025 1 and is seen as a growth driver alongside sports medicine.
Sports Medicine & ENT
The unit providing products and instruments to repair or remove soft tissue, with revenue of 1.934 bn USD in 2025 1. The company aims for higher share here through innovation and targeted acquisitions, including the January 2026 acquisition of Integrity Orthopaedics 1.
Orthopaedics
Includes hip, knee and shoulder replacement systems, robotics-assisted solutions and trauma products. The segment generated 1.793 bn USD in 2025 1 and is in a recovery phase, with a target to expand trading profit margin.
Market context
The company states that it operates in global markets valued at more than 50 bn USD annually 1. Demand is supported by an ageing population, rising chronic conditions and technological innovation, and in emerging markets by a growing middle class seeking better healthcare 1. Revenue in 2025 reached 6.164 bn USD 1.
Trends
- Ageing populationtailwind
A growing number of older people increases demand for orthopaedic procedures and age-related treatments, according to the report 1.
- Technological innovation and roboticstailwind
Robotic systems and digital solutions could expand the market and shift procedures from hospitals to ambulatory centres, as the company argues 1.
- Price pressure in Chinaheadwind
Volume Based Procurement tenders in China created difficulties in recent years, according to company statements 1.
- Cost discipline versus restructuringmixed
Productivity programmes could support margins, but portfolio rationalisation has temporarily weighed on returns 1.
Competitive position
The annual report does not explicitly name competitors in the supplied source. The company describes its markets as shaped by global medical technology players, and its expansion in sports medicine and orthopaedics means facing established manufacturers 1.
- Other global medical technology manufacturers
The source does not name competitors; the company only notes that the sector is led by global players with accelerating innovation 1.
- Makers of robotic surgery systems
Competition in robot-assisted orthopaedics is mentioned only generically in the company's strategy 1.
- Suppliers of soft tissue repair solutions
The sports medicine segment is described as a market with unmet clinical needs and competition for innovation 1.
- Wound management device producers
The advanced wound management unit competes in dressings and negative pressure wound therapy 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)22 Oct 2026
- Current report (foreign issuer)08 Oct 2026
- Current report (foreign issuer)01 Oct 2026
- Current report (foreign issuer)01 Oct 2026
- Current report (foreign issuer)18 Sept 2026
- Current report (foreign issuer)18 Sept 2026
- Current report (foreign issuer)16 Sept 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Smith+Nephew plc · 16 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.